Could a common blood pressure pill ease muscle stiffness? early trial launches
NCT ID NCT07075965
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests amlodipine, a calcium channel blocker used for high blood pressure, in 20 adults with myotonic dystrophy type 1. The goal is to see if the drug is safe and can improve muscle strength, reduce stiffness, and help with daily function. All participants will take the drug for 10 weeks, with some getting a higher dose after the first month. Results will guide a larger future study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amlodipine (a calcium channel blocker, commonly used for high blood pressure)
- What this could lead to
- If safe and effective, this could point toward a treatment to improve muscle strength and reduce stiffness in people with myotonic dystrophy type 1.
- What could go wrong
- This is a very early Phase 1 trial with only 20 people, focused on safety. It may not show clear benefit, and side effects like low blood pressure or dizziness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can watching the course of myotonic dystrophy unlock better care?
- Scientists hunt for biomarkers to unlock DM1 treatments
- 700-Patient study seeks key clues to muscle disease
- Brain scans reveal diabetes link to cognitive decline in rare disease
- New drug AOC 1001 tested for rare muscle disease
- Spanish researchers launch massive DM1 registry to unlock disease secrets